Adel Esraa M, Elberry Ahmed A, Abdel Aziz Ahmed, Naguib Ibrahim A, Alghamdi Badrah S, Hussein Raghda R S
National Heart Institute, Cairo 12461, Egypt.
Department of Pharmacy Practice, Pharmacy Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia.
J Clin Med. 2022 Aug 31;11(17):5142. doi: 10.3390/jcm11175142.
The aim of this study was to compare the effect of a single high-dose rosuvastatin versus atorvastatin preloading in ST-elevation myocardial infarction (STEMI) patients receiving primary percutaneous coronary intervention (PCI.) Methods: A total of 99 patients presented with STEMI and were randomly divided into three groups—a control group (n = 33) with no statin treatment, an atorvastatin group (n = 33) with a single 80 mg atorvastatin dose and the rosuvastatin group (n = 33) with a single 40 mg rosuvastatin dose in the emergency room (ER) prior to PCI. Post-interventional thrombolysis in myocardial infarction (TIMI) flow grade and corrected TIMI frame count (CTFC) were recorded, and ST-segment resolution was measured. Results: CTFC was significantly lower for the atorvastatin group (p-value < 0.01) than in the control group. A final TIMI flow grade 3 was achieved in 32 (97.0%) patients in the rosuvastatin group and 28 (84.8%) patients in the atorvastatin group compared with only 25 (75.8%) patients in the control group (p = 0.014). Peak CK-MB in the rosuvastatin group (263.2 [207.2−315.6]) and the atorvastatin group (208 [151.0−314.1]) was lower compared to that in the control group (398.4 [303.9−459.3]); p < 0.001. Conclusions: A single extensive dose of lipophilic atorvastatin prior to primary PCI in STEMI patients showed better improvement in microvascular myocardial perfusion compared to hydrophilic rosuvastatin.
本研究旨在比较单次大剂量瑞舒伐他汀与阿托伐他汀预负荷对接受直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者的影响。方法:共有99例STEMI患者,随机分为三组——未接受他汀类药物治疗的对照组(n = 33)、在PCI前于急诊室(ER)接受单次80 mg阿托伐他汀剂量的阿托伐他汀组(n = 33)和接受单次40 mg瑞舒伐他汀剂量的瑞舒伐他汀组(n = 33)。记录介入治疗后的心肌梗死溶栓(TIMI)血流分级和校正TIMI帧数(CTFC),并测量ST段回落情况。结果:阿托伐他汀组的CTFC显著低于对照组(p值<0.01)。瑞舒伐他汀组32例(97.0%)患者和阿托伐他汀组28例(84.8%)患者最终达到TIMI血流3级,而对照组仅25例(75.8%)患者达到(p = 0.014)。瑞舒伐他汀组(263.2 [207.2−315.6])和阿托伐他汀组(208 [151.0−314.1])的肌酸激酶同工酶(CK-MB)峰值低于对照组(398.4 [303.9−459.3]);p < 0.001。结论:与亲水性的瑞舒伐他汀相比,STEMI患者在直接PCI前单次大剂量使用亲脂性的阿托伐他汀在微血管心肌灌注方面显示出更好的改善。